{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:57:21Z","timestamp":1778626641681,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/leu.2013.245","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T06:37:19Z","timestamp":1376980639000},"page":"761-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL"],"prefix":"10.1038","volume":"28","author":[{"given":"J A P","family":"Spijkers-Hagelstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S S","family":"Pinhan\u00e7os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R W","family":"Stam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"key":"BFleu2013245_CR1","first-page":"372","volume":"10","author":"MF Greaves","year":"1996","unstructured":"Greaves MF . Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10: 372\u2013377.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240\u2013250.","journal-title":"Lancet"},{"key":"BFleu2013245_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"CH Pui","year":"2004","unstructured":"Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535\u20131548.","journal-title":"N Engl J Med"},{"key":"BFleu2013245_CR4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","volume":"12","author":"R Pieters","year":"1998","unstructured":"Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia\u2014implications for treatment of infants. Leukemia 1998; 12: 1344\u20131348.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","volume":"94","author":"M Dordelmann","year":"1999","unstructured":"Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209\u20131217.","journal-title":"Blood"},{"key":"BFleu2013245_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00043426-199701000-00005","volume":"19","author":"LS Frankel","year":"1997","unstructured":"Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19: 35\u201342.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFleu2013245_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.1999.17.2.445","volume":"17","author":"GH Reaman","year":"1999","unstructured":"Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445\u2013455.","journal-title":"J Clin Oncol"},{"key":"BFleu2013245_CR8","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Den Boer","year":"2003","unstructured":"Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262\u20133268.","journal-title":"J Clin Oncol"},{"key":"BFleu2013245_CR9","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","volume":"90","author":"GJ Kaspers","year":"1997","unstructured":"Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723\u20132729.","journal-title":"Blood"},{"key":"BFleu2013245_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa033513","volume":"351","author":"A Holleman","year":"2004","unstructured":"Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351: 533\u2013542.","journal-title":"N Engl J Med"},{"key":"BFleu2013245_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"G Wei","year":"2006","unstructured":"Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331\u2013342.","journal-title":"Cancer Cell"},{"key":"BFleu2013245_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929\u20131935.","journal-title":"Science"},{"key":"BFleu2013245_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nrc2044","volume":"7","author":"J Lamb","year":"2007","unstructured":"Lamb J . The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54\u201360.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2013245_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1182\/blood-2009-02-205963","volume":"115","author":"RW Stam","year":"2010","unstructured":"Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010; 115: 1018\u20131025.","journal-title":"Blood"},{"key":"BFleu2013245_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","volume":"1","author":"EJ Yeoh","year":"2002","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133\u2013143.","journal-title":"Cancer Cell"},{"key":"BFleu2013245_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ng765","volume":"30","author":"SA Armstrong","year":"2002","unstructured":"Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41\u201347.","journal-title":"Nat Genet"},{"key":"BFleu2013245_CR17","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2009-07-233049","volume":"115","author":"RW Stam","year":"2010","unstructured":"Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835\u20132844.","journal-title":"Blood"},{"key":"BFleu2013245_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/leu.2012.372","volume":"27","author":"JA Spijkers-Hagelstein","year":"2012","unstructured":"Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, Pieters R, Stam RW . Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2012; 27: 1063\u20131071.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/bjc.1994.446","volume":"70","author":"GJ Kaspers","year":"1994","unstructured":"Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047\u20131052.","journal-title":"Br J Cancer"},{"key":"BFleu2013245_CR20","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V76.11.2327.2327","volume":"76","author":"R Pieters","year":"1990","unstructured":"Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327\u20132336.","journal-title":"Blood"},{"key":"BFleu2013245_CR21","first-page":"1","volume":"28","author":"MC Berenbaum","year":"1977","unstructured":"Berenbaum MC . Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977; 28: 1\u201318.","journal-title":"Clin Exp Immunol"},{"key":"BFleu2013245_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/sj.leu.2403253","volume":"18","author":"NL Ramakers-van Woerden","year":"2004","unstructured":"Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004; 18: 521\u2013529.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/j.1349-7006.2007.00693.x","volume":"99","author":"D Kong","year":"2008","unstructured":"Kong D, Yamori T . Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 2008; 99: 1734\u20131740.","journal-title":"Cancer Sci"},{"key":"BFleu2013245_CR24","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-09-4355","volume":"70","author":"P Workman","year":"2010","unstructured":"Workman P, Clarke PA, Raynaud FI, van Montfort RL . Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146\u20132157.","journal-title":"Cancer Res"},{"key":"BFleu2013245_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.leu.2402708","volume":"17","author":"L Munoz","year":"2003","unstructured":"Munoz L, Nomdedeu JF, Villamor N, Guardia R, Colomer D, Ribera JM et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76\u201382.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR26","first-page":"8414","volume":"63","author":"MK Tur","year":"2003","unstructured":"Tur MK, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003; 63: 8414\u20138419.","journal-title":"Cancer Res"},{"key":"BFleu2013245_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/152581601750098318","volume":"10","author":"RK Zhong","year":"2001","unstructured":"Zhong RK, van de Winkel JG, Thepen T, Schultz LD . Ball ED Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res 2001; 10: 95\u2013105.","journal-title":"J Hematother Stem Cell Res"},{"key":"BFleu2013245_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1365-2141.2004.04933.x","volume":"125","author":"SB Marley","year":"2004","unstructured":"Marley SB, Lewis JL, Schneider H, Rudd CE, Gordon MY . Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol 2004; 125: 500\u2013511.","journal-title":"Br J Haematol"},{"key":"BFleu2013245_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.leu.2403653","volume":"19","author":"VL Grandage","year":"2005","unstructured":"Grandage VL, Gale RE, Linch DC, Khwaja A . PI3-kinase\/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586\u2013594.","journal-title":"Leukemia"},{"key":"BFleu2013245_CR30","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2008-09-179812","volume":"114","author":"H Edwards","year":"2009","unstructured":"Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL et al. RUNX1 regulates phosphoinositide 3-kinase\/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009; 114: 2744\u20132752.","journal-title":"Blood"},{"key":"BFleu2013245_CR31","first-page":"234","volume":"1","author":"LM Neri","year":"2003","unstructured":"Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G et al. The phosphoinositide 3-kinase\/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234\u2013246.","journal-title":"Mol Cancer Res"},{"key":"BFleu2013245_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/jcp.20153","volume":"202","author":"G Tabellini","year":"2005","unstructured":"Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L et al. Phosphoinositide 3-kinase\/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005; 202: 623\u2013634.","journal-title":"J Cell Physiol"},{"key":"BFleu2013245_CR33","doi-asserted-by":"publisher","first-page":"14602","DOI":"10.1038\/sj.leu.2401726","volume":"14","author":"DM O'Gorman","year":"2000","unstructured":"O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. . Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000; 14: 14602\u201314611.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013245","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:24:50Z","timestamp":1648740290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFleu2013245"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.245","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]},"assertion":[{"value":"13 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}